VERU - Veru Inc Stock Price, Fair Value and News

0.94USD-0.01 (-1.05%)Market Closed

Market Summary

USD0.94-0.01

Market Closed

-1.05%

VERU Stock Price

View Fullscreen

VERU RSI Chart

VERU Valuation

Market Cap

139.1M

Price/Earnings (Trailing)

-3.57

Price/Sales (Trailing)

10.32

EV/EBITDA

-3.75

Price/Free Cashflow

-5.16

VERU Price/Sales (Trailing)

VERU Profitability

EBT Margin

-283.64%

Return on Equity

-86.17%

Return on Assets

-54.26%

Free Cashflow Yield

-19.37%

VERU Fundamentals

VERU Revenue

Revenue (TTM)

13.5M

Rev. Growth (Yr)

-37.21%

Rev. Growth (Qtr)

93.17%

VERU Earnings

Earnings (TTM)

-39.0M

Earnings Growth (Yr)

70.33%

Earnings Growth (Qtr)

-21.15%

Breaking Down VERU Revenue

Last 30 days

19.0%

Last 90 days

-26.0%

Trailing 12 Months

-22.9%

How does VERU drawdown profile look like?

VERU Financial Health

Current Ratio

4.72

Debt/Equity

0.04

Debt/Cashflow

-23.26

VERU Investor Care

Dividend Yield

14.79%

Dividend/Share (TTM)

0.21

Shares Dilution (1Y)

64.04%

Diluted EPS (TTM)

-0.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	13.5M	0	0	0
2023	21.3M	15.0M	16.3M	15.9M
2022	60.5M	52.4M	39.4M	27.7M
2021	50.0M	57.4M	61.3M	60.8M
2020	39.0M	39.6M	42.6M	46.6M
2019	24.1M	28.3M	31.8M	36.0M
2018	13.2M	14.4M	15.9M	19.6M
2017	14.8M	13.5M	13.7M	13.0M
2016	28.0M	25.7M	22.1M	17.1M
2015	31.1M	31.0M	32.6M	34.2M
2014	23.1M	23.7M	24.5M	24.5M
2013	38.0M	36.6M	31.5M	28.2M
2012	27.1M	32.2M	35.0M	36.3M
2011	20.4M	19.5M	18.6M	23.5M
2010	0	24.9M	22.2M	21.3M
2009	0	0	27.5M	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Veru Inc

Veru Inc., a biopharmaceutical company, focuses on developing medicines for the management of COVID-19, and breast and prostate cancers. Its commercial products comprise FC2 female condom/internal condom for the protection against unintended pregnancy and the transmission of sexually transmitted infections; and Entadfi, a capsule for the treatment of urinary tract symptoms. The company's drug candidates under development include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase 2b clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer. In addition, its drug candidate also comprise Sabizabulin, which is in Phase 3 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase 2b clinical trial for treating hot flashes; and Sabizabulin, an oral microtubule disruptor with dual antiviral and anti-inflammatory to severe COVID-19 patients at risk for acute respiratory distress syndrome. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

CEO	Dr. Mitchell S. Steiner F.A.C.S, F.A.C.S., M.D.
WEBSITE	verupharma.com
INDUSTRY	Biotechnology
EMPLOYEES	233

Veru Inc Frequently Asked Questions

What is the ticker symbol for Veru Inc? What does VERU stand for in stocks?

VERU is the stock ticker symbol of Veru Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Veru Inc (VERU)?

As of Thu Jul 25 2024, market cap of Veru Inc is 139.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VERU stock?

You can check VERU's fair value in chart for subscribers.

Is Veru Inc a good stock to buy?

The fair value guage provides a quick view whether VERU is over valued or under valued. Whether Veru Inc is cheap or expensive depends on the assumptions which impact Veru Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VERU.

What is Veru Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, VERU's PE ratio (Price to Earnings) is -3.57 and Price to Sales (PS) ratio is 10.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VERU PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Veru Inc's stock?

In the past 10 years, Veru Inc has provided -0.138 (multiply by 100 for percentage) rate of return.